Joint Meeting of the Nonprescription Drugs and

the Pulmonary-Allergy Drugs Advisory Committees 

January 24, 2006

Continued need for designation of over-the-counter (OTC) epinephrine-metered dose inhalers

 for the treatment of asthma as an essential use of ozone-depleting substances (ODSs) under 21 CFR 2.125

Slides Presented at Meeting

Welcome and Introductory Comments

[HTML]   [PPT]

Charles Ganley, M.D.

Director, Office of Nonprescription Products

FDA Presentation

[HTML]   [PPT]

Robert J. Meyer, M.D.

Director, Office of Drug Evaluation II

Wyeth Consumer Healthcare Products

[HTML]   [PPT]

Roger Berlin, M.D.

President of Scientific Affairs

Wyeth Consumer Healthcare

Open Public Hearing Speakers

[HTML]   [PPT]

Sandra Fusco-Walker

Allergy & Asthma Network

Mothers of Astyhmatics

[HTML]   [PPT]

Questions

[HTML]   [PPT]